Most Read Articles
Elvira Manzano, 4 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
20 hours ago
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.
Tristan Manalac, 22 hours ago
Statin use, particularly in smokers, obese patients and nondiabetics, has a strong and dose-dependent association with decreasing risk of pancreatic ductal adenocarcinoma (PDAC), according to a new study.

Add-on lesinurad helps lower serum urate in gout patients uncontrolled on febuxostat

23 Aug 2017

The addition of lesinurad to febuxostat appears to provide superior serum urate (sUA)-lowering benefit compared with febuxostat alone, with acceptable safety profile and clinically significant effect on tophi, in patients with tophaceous gout requiring additional therapy, according to the results of a 12-month, phase III trial.

A total of 324 patients (mean age 54.1 years; 95.4 percent male) with sUA ≥8.0 mg/dl (≥6.0 mg/dl on urate-lowering therapy) and ≥1 measurable target tophus were randomized to receive lesinurad (200 or 400mg daily) or placebo as add-on to febuxostat, which was initiated at a once-daily dose of 80 mg 3 weeks prior to randomization.

The respective primary and secondary endpoints were the proportion of patients achieving sUA <5.0 mg/dl at month 6 and the proportion of those with complete resolution of ≥1 target tophus at month 12. Percent change in total target tophi area was also evaluated. Assessments were performed at baseline, week 2 and months 1 to 6, 8, 10, and 12 for sUA and every 3 months for tophi.

The proportion of patients achieving sUA target by month 6 was significantly greater with lesinurad 400 mg vs placebo (76.1 vs 46.8 percent; p<0.0001). No significant difference was observed between lesinurad 200 mg and placebo (56.6 vs 46.8 percent; p=0.13). At all other time points, significantly more patients in the lesinurad 200 mg arm achieved the sUA target.

Complete tophus resolution was comparable among the treatment groups. However, reductions in total target tophi area was significantly greater with lesinurad (200 and 400 mg) than with placebo (50.1 and 52.9 percent vs 28.3 percent; p<0.05).

Lesinurad plus febuxostat demonstrated a safety profile that was generally comparable with febuxostat alone, except for higher rates of predominately reversible serum creatinine elevation, particularly with the 400 mg dose.

Lesinurad 200 mg is a novel selective uric acid reabsorption inhibitor approved for treatment of gout in combination with a xanthine oxidase inhibitor (XOI) in patients who do not achieve target sUA levels on an XOI alone, researchers said.

“Combination therapy with lesinurad and febuxostat provides a dual mechanism, addressing both uric acid excretion and urate production, and may represent a treatment option for patients with tophaceous gout on febuxostat who warrant additional therapy,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 4 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
20 hours ago
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.
Tristan Manalac, 22 hours ago
Statin use, particularly in smokers, obese patients and nondiabetics, has a strong and dose-dependent association with decreasing risk of pancreatic ductal adenocarcinoma (PDAC), according to a new study.